, /PRNewswire/ - Today, , a Canadian drug development company, announced IBEX011, the first GMP extract of available for use in ibogaine clinics and academic research. IBEX011 also marks the first time that an ibogaine product is compliant with the , a UN treaty which ensures equitable benefits for traditional knowledge holders from the Bwiti tradition in . Iboga root bark has been used for millennia for traditional healing and initiation rites, and more recently in international clinics that treat drug addiction and neurological conditions, including traumatic brain injury.
, the world's largest medical ibogaine facility, treating over 50 patients a month, will be the first clinic to use Terragnosis' iboga extract with patients. , the CEO of both Terragnosis and Ambio, said, "This marks a common-sense shift in how we think about the production of psychedelic medicine. We've gone back to the source to build relationships with the most experienced practitioners.
Our goal is to offer the product with the most potent healing properties." While most ibogaine in use today is produced semi-synthetically using chemicals extracted from alternative plant sources, IBEX011 contains all of the naturally occurring alkaloids found in root bark. This new extract is at least 30% stronger by weight than single molecule ibogaine products.
"What we've seen so far has surprised us," said Ambio co-founder and Chief Operations Officer . "We're excited to demonstrate what a standardized botanical l.
